{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:15:00Z","timestamp":1793661300366,"version":"4.5.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Almost 300\u00a0million people are living with chronic hepatitis B infection worldwide and most remain undiagnosed and at risk for liver cancer. In 2015 the World Health Organization (WHO) developed guidelines for the prevention, care, and treatment of persons with chronic hepatitis B and in early 2023 began to work on updating these guidelines. In March 2023, a self-administered, anonymous online survey was launched, aiming to identify patient preferences related to the clinical management of hepatitis B including current management, treatment, and care experiences, preferences regarding engagement with providers, and preferences related to simplifying hepatitis B care access. A sample of 560 individuals living with hepatitis B (self-identified as HBsAg positive) from 76 countries completed the survey. Key findings demonstrated that less than half (49%, <jats:italic>N<\/jats:italic>\u2009=\u2009268) of participants regularly visited a doctor to check the health of their liver (every 6\u201312 months), with 37% of participants prescribed antiviral medication by a specialist (82%, <jats:italic>N<\/jats:italic>\u2009=\u2009167) or general practitioner (13%, <jats:italic>N<\/jats:italic>\u2009=\u200926). Participants reported not being actively involved in care decision making with their providers (42%, <jats:italic>N<\/jats:italic>\u2009=\u2009217), with an overwhelming majority wanting to participate in hepatitis B management and treatment choices (85%, <jats:italic>N<\/jats:italic>\u2009=\u2009435). Participants provided qualitative and quantitative details using open-ended responses within the survey about challenges with medication affordability and receiving care from a knowledgeable provider. Overall findings demonstrated key gaps in care, management, and treatment access related to hepatitis B: identifying these gaps can be used to identify areas for improvement along the care continuum for viral hepatitis. The survey found a need for the comprehensive simplification of clinical management and health care services related to hepatitis B. A thematic analysis of the open-ended survey responses highlighted major overarching themes including the cost and access burdens associated with hepatitis B management and treatment, and challenges in finding knowledgeable providers. Results from this mixed methods survey were used to inform the WHO hepatitis B guidelines update. Efforts should continue to explore public health approaches to address barriers and facilitators to testing, care, and treatment for people with hepatitis B to improve awareness of hepatitis B and access, care, and treatment among patients and providers.<\/jats:p>","DOI":"10.1186\/s12889-024-18425-w","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T08:01:55Z","timestamp":1712044915000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Survey of lived experiences and challenges in hepatitis B management and treatment"],"prefix":"10.1186","volume":"24","author":[{"given":"Catherine","family":"Freeland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danjuma","family":"Adda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chari","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"18425_CR1","unstructured":"WHO. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021. Vol 53.; 2021."},{"key":"18425_CR2","unstructured":"World Health Organisation. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021. Vol 53. 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240027077."},{"issue":"6","key":"18425_CR3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","volume":"3","author":"D Polaris Observatory Collaborators","year":"2018","unstructured":"Polaris Observatory Collaborators D, Gamkrelidze I, Nguyen MH, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383\u2013403. https:\/\/doi.org\/10.1016\/S2468-1253(18)30056-6.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"18425_CR4","unstructured":"Global Strategy on HIV viral. hepatitis and sexually transmitted infections. 9789240053779-Eng (1).; 2022."},{"issue":"10348","key":"18425_CR5","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0140-6736(22)01377-0","volume":"400","author":"The Lancet","year":"2022","unstructured":"The Lancet. Viral hepatitis elimination: a challenge, but within reach. Lancet. 2022;400(10348):251. https:\/\/doi.org\/10.1016\/S0140-6736(22)01377-0.","journal-title":"Lancet"},{"issue":"6","key":"18425_CR6","doi-asserted-by":"publisher","first-page":"816","DOI":"10.5604\/16652681.1222096","volume":"15","author":"R Zampino","year":"2016","unstructured":"Zampino R, Sagnelli C, Boemio A, Sagnelli E, Coppola N. Treatment of chronic HBV infection in developing countries. Ann Hepatol. 2016;15(6):816\u201323. https:\/\/doi.org\/10.5604\/16652681.1222096.","journal-title":"Ann Hepatol"},{"key":"18425_CR7","doi-asserted-by":"publisher","unstructured":"Reipold EI, Trianni A, Krakower D, et al. Values, preferences and current hepatitis B and C testing practices in low- and middle-income countries: results of a survey of end users and implementers. BMC Infect Dis. 2017;17. https:\/\/doi.org\/10.1186\/s12879-017-2769-y.","DOI":"10.1186\/s12879-017-2769-y"},{"key":"18425_CR8","unstructured":"GUIDELINES FOR THE PREVENTION, CARE AND TREATMENT OF PERSONS. WITH CHRONIC HEPATITIS B INFECTION.; 2015."},{"key":"18425_CR9","doi-asserted-by":"publisher","unstructured":"Freeland C, Farrell S, Kumar P, et al. Common concerns, barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study. BMC Public Health. 2021;21(1). https:\/\/doi.org\/10.1186\/s12889-021-11093-0.","DOI":"10.1186\/s12889-021-11093-0"},{"issue":"4","key":"18425_CR10","doi-asserted-by":"publisher","first-page":"748","DOI":"10.4103\/jfmpc.jfmpc_1575_22","volume":"12","author":"M Tomar","year":"2023","unstructured":"Tomar M, Sharma T, Prasad M. Social challenges experienced by Hepatitis B patients: a mixed method study. J Family Med Prim Care. 2023;12(4):748. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_1575_22.","journal-title":"J Family Med Prim Care"},{"issue":"1","key":"18425_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12939-022-01677-6","volume":"21","author":"C Freeland","year":"2022","unstructured":"Freeland C, Mendola L, Cheng V, Cohen C, Wallace J. The unvirtuous cycle of discrimination affecting people with hepatitis B: a multi-country qualitative assessment of key-informant perspectives. Int J Equity Health. 2022;21(1):1\u201310. https:\/\/doi.org\/10.1186\/s12939-022-01677-6.","journal-title":"Int J Equity Health"},{"key":"18425_CR12","doi-asserted-by":"publisher","unstructured":"Ishizaki A, Bouscaillou J, Luhmann N, et al. Survey of programmatic experiences and challenges in delivery of hepatitis B and C testing in low- and middle-income countries. BMC Infect Dis. 2017;17. https:\/\/doi.org\/10.1186\/s12879-017-2767-0.","DOI":"10.1186\/s12879-017-2767-0"},{"issue":"6","key":"18425_CR13","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.4269\/ajtmh.16-0398","volume":"95","author":"T Giles-Vernick","year":"2016","unstructured":"Giles-Vernick T, Hejoaka F, Sanou A, Shimakawa Y, Bamba I, Traor\u00e9 A. Barriers to linkage to care for hepatitis b virus infection: a qualitative analysis in Burkina Faso, West Africa. Am J Trop Med Hyg. 2016;95(6):1368\u201375. https:\/\/doi.org\/10.4269\/ajtmh.16-0398.","journal-title":"Am J Trop Med Hyg"},{"key":"18425_CR14","doi-asserted-by":"publisher","unstructured":"Li T, Su S, Zhao Y, et al. Barriers to the prevention and control of hepatitis B and hepatitis C in the community of southwestern China: a qualitative research. Int J Environ Res Public Health. 2019;16(2). https:\/\/doi.org\/10.3390\/ijerph16020231.","DOI":"10.3390\/ijerph16020231"},{"key":"18425_CR15","doi-asserted-by":"publisher","unstructured":"Adjei CA, Stutterheim SE, Naab F, Ruiter RAC. Barriers to chronic Hepatitis B treatment and care in Ghana: a qualitative study with people with Hepatitis B and healthcare providers. PLoS ONE. 2019;14(12). https:\/\/doi.org\/10.1371\/journal.pone.0225830.","DOI":"10.1371\/journal.pone.0225830"},{"key":"18425_CR16","unstructured":"World Health Organization Africa Region. HIV\/AIDS."},{"key":"18425_CR17","doi-asserted-by":"crossref","unstructured":"Nash D, Yotebieng M, Sohn AH. Treating All People Living with HIV in Sub-Saharan Africa: A New Era Calling for New Approaches. Vol 4.; 2018.","DOI":"10.1016\/S2055-6640(20)30340-X"},{"key":"18425_CR18","doi-asserted-by":"publisher","unstructured":"Van Le T, Vu TTM, Mai HT, et al. Social determinants of stigma and discrimination in Vietnamese patients with chronic hepatitis B. Int J Environ Res Public Health. 2019;16(3). https:\/\/doi.org\/10.3390\/ijerph16030398.","DOI":"10.3390\/ijerph16030398"},{"issue":"4","key":"18425_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0195455","volume":"13","author":"B Han","year":"2018","unstructured":"Han B, Yuan Q, Shi Y, et al. The experience of discrimination of individuals living with chronic hepatitis B in four provinces of China. PLoS ONE. 2018;13(4):1\u201310. https:\/\/doi.org\/10.1371\/journal.pone.0195455.","journal-title":"PLoS ONE"},{"key":"18425_CR20","doi-asserted-by":"publisher","unstructured":"Thi MDA, Brickley DB, Vinh DTN et al. A qualitative study of stigma and discrimination against people living with HIV in Ho Chi Minh City, Vietnam. AIDS Behav. 2008;12(SUPPL. 1). https:\/\/doi.org\/10.1007\/s10461-008-9374-4.","DOI":"10.1007\/s10461-008-9374-4"},{"issue":"3","key":"18425_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/19371918.2018.1434584","volume":"33","author":"LH D\u2019Anna","year":"2018","unstructured":"D\u2019Anna LH, Hansen M, Mull B, Canjura C, Lee E, Sumstine S. Social discrimination and health care: a multidimensional framework of experiences among a low-income multiethnic sample. Soc Work Public Health. 2018;33(3):187\u2013201. https:\/\/doi.org\/10.1080\/19371918.2018.1434584.","journal-title":"Soc Work Public Health"}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18425-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-024-18425-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-024-18425-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T08:04:13Z","timestamp":1712045053000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-024-18425-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["18425"],"URL":"https:\/\/doi.org\/10.1186\/s12889-024-18425-w","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"assertion":[{"value":"5 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Chari Cohen: Hepatitis B Foundation receives educational, programmatic and research grants from Gilead Sciences, GSK and VBI Vaccines. C Cohen serves on a patient\/advocate advisory council Gilead Sciences, GSK and Roche (as a representative of the Hepatitis B Foundation). Catherine Freeland has served on the patient advisory boards for Gilead Sciences and GSK. Other authors have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"944"}}